Abstracts

Articles appearing in the March 2019 issue

Mouse model of anti-NMDA receptor post-herpes simplex encephalitis

Objective To develop an endogenous rodent model of postinfectious anti-NMDA receptor (NMDAR) encephalitis.

Methods Six mice were inoculated intranasally with herpes simplex virus (HSV) 1 and subsequently treated with acyclovir for 2 weeks. Serum was collected at 3, 6, and 8 weeks postinoculation and tested for NMDAR antibodies through a cell-based assay. Eight weeks postinoculation, mice were killed and their brains were sectioned and immunostained with antibodies to postsynaptic density (PSD)-95 and NMDARs. Colocalization of hippocampal PSD-95 and NMDAR clusters, representing postsynaptic membrane NMDARs, was quantified via confocal imaging. Hippocampi were additionally analyzed for NMDAR and PSD-95 protein using Western blot analysis.

Results Four of 6 mice (67%) developed serum antibodies to NMDARs: 1 at 3 weeks, 1 at 6 weeks, and 2 at 8 weeks postinoculation. As compared to inoculated mice that did not develop NMDAR antibodies, immunofluorescence staining revealed decreased hippocampal postsynaptic membrane NMDARs in mice with serum antibodies at 8 weeks postinoculation. Western blot analysis showed that mice that had NMDAR antibodies at 8 weeks had decreased total NMDAR but not PSD-95 protein in hippocampal extracts ($p < 0.05$).

Conclusions Mice inoculated intranasally with HSV-1 developed serum NMDAR antibodies. These antibodies were associated with reduced hippocampal NMDARs, as has been shown in previous models where antibodies from patients with anti-NMDAR encephalitis were infused into mice, paving the way for future studies into the pathophysiology of autoimmune encephalitides.

[NPub.org/N2/9306a](https://pubmed.ncbi.nlm.nih.gov/30906606/)

MRI phenotypes in MS: Longitudinal changes and miRNA signatures

Objective To classify and immunologically characterize persons with multiple sclerosis (MS) based on brain lesions and atrophy and their associated microRNA profiles.

Methods Cerebral T2-hyperintense lesion volume (T2LV) and brain parenchymal fraction (BPF) were quantified and used to define MRI phenotypes as follows: type I: low T2LV, low atrophy; type II: high T2LV, low atrophy; type III: low T2LV, high atrophy; type IV: high T2LV, high atrophy, in a large cross-sectional cohort ($n = 1,088$) and a subset with 5-year longitudinal follow-up ($n = 153$). Serum miRNAs were assessed on a third MS cohort with 2-year MRI phenotype stability ($n = 98$).

Results One-third of the patients had lesion-atrophy dissociation (types II or III) in both the cross-sectional and longitudinal cohorts. At 5 years, all phenotypes had progressive atrophy ($p < 0.001$), disproportionately in type II (BPF -2.28%). Only type IV worsened in physical disability. Types I and II showed a 5-year MRI phenotype conversion rate of 33% and 46%, whereas III and IV had $>90\%$ stability. Type II switched primarily to IV (91%); type I switched primarily to II (47%) or III (37%). Baseline higher age ($p = 0.006$) and lower BPF ($p < 0.001$) predicted 5-year phenotype conversion. Each MRI phenotype demonstrated an miRNA signature whose underlying biology implicates blood-brain barrier pathology: hsa.miR.22.3p, hsa.miR.361.5p, and hsa.miR.345.5p were the most valid differentiators of MRI phenotypes.

Conclusions MRI-defined MS phenotypes show high conversion rates characterized by the continuation of either predominant neurodegeneration or inflammation and support the partial independence of these 2 measures. MicroRNA signatures of these phenotypes suggest a role for blood-brain barrier integrity.

[NPub.org/N2/9306b](https://pubmed.ncbi.nlm.nih.gov/30906606/)

Most-Read Articles

As of February 22, 2019

New type of encephalomyelitis responsive to trimethoprim/sulfamethoxazole treatment in Japan

Y. Sakiyama, N. Kanda, Y. Higuchi, et al. 2015;2:e143. doi.org/10.1212/NXI.0000000000000143

Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment

J. Shubert, D. Brämer, H.B. Huttner, et al. 2019;6:e514. doi.org/10.1212/NXI.0000000000000514

Real-world validation of the 2017 McDonald criteria for pediatric MS

Y.Y.M. Wong, C. Louk de Mol, R.M. van der Vuurst de Vries, et al. 2019;6:e528. doi.org/10.1212/NXI.0000000000000528

Balint syndrome in anti-NMDA receptor encephalitis

A. Metzger, L. Pisella, A. Vighetto, et al. 2019;6:e532. doi.org/10.1212/NXI.0000000000000532

Inflammatory myopathy with myasthenia gravis: thymoma association and polymyositis pathology

N. Uchio, K. Taira, C. Ikenaga, et al. 2019;6:e535. doi.org/10.1212/NXI.0000000000000535

Neurology[®]

What's happening in *Neurology*[®] *Neuroimmunology* & *Neuroinflammation*
Neurology 2019;93;250
DOI 10.1212/WNL.0000000000007900

This information is current as of August 5, 2019

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/93/6/250.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology[®] is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.